Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Covidien

- PMLiVE

AZ swells immuno-oncology pipeline with Innate deal

Deal gives access to natural killer cell immunotherapy

- PMLiVE

Merck’s Bavencio joins first-line kidney cancer face-off

PD-L1 and TKI combination could challenge standard of care

- PMLiVE

Dynavax is ‘deal-ready’ after solid ESMO data; analyst

Contrasting results for two novel immunotherapies

- PMLiVE

Cancer care – the power of new technologies

With patient numbers set to soar, how can we make a difference?

- PMLiVE

BMS finds a new immunotherapy partner with $12m Compugen deal

Combination with novel antibody targeting PVRIG pathway

- PMLiVE

Armoured CAR ‘could overwhelm solid tumour resistance’

Eureka Therapeutics and Memorial Sloan Kettering approach shows promise

- PMLiVE

Cancer immunotherapy: What’s on the horizon?

Old and new therapies

- PMLiVE

Mallinckrodt doses first patient in muscular dystrophy trial

Repurposed drug could help delay decline in muscle function

- PMLiVE

Daily Brief: Karuna raises $42m for novel CNS approach, Chen exits Roche, Orchard gains GSK board member

The latest from pharma, biotech and healthcare

- PMLiVE

China’s BeiGene takes PD-1 antibody into pivotal trials

Firm aims to leapfrog immunotherapy leaders in huge market

- PMLiVE

Vyriad inks immunotherapy alliance with Merck/Pfizer

Genetically engineered virus produces immune response in tumours

- PMLiVE

Christina Coughlin to leave Immunocore for Tmunity

UPenn pioneers building their own biotech company

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links